|
|
|
Influenza Antibody Spray Success: Opens New Approach to Respiratory Disease Control
Posted By: Anonymous | Posted On: Aug 20,2008 18:30 pm | View: 25
Anadis Limited (ASX: ANX), a research driven biopharmaceutical company focused on polyclonal antibodies to address human disease, announced today important progress concerning its accelerated program to develop a nasal antibody spray to provide immediate post-exposure prophylaxis against a range of influenza viruses.
Read More: http://www.prweb.com/releases/anadis/influenza/prweb1235744.htm
|
|
|
|